model,flat_path,key_cat,val_cat,ref_val,pred_val,val_match,sim,score_status,piece,norm_path,from_pred,in_ref,in_pred,type_mismatch,is_enum,sim_failed
GPT-5.1,protocolSection.identificationModule.nctId,TP,TP,NCT02137499,NCT02137499,True,1.0,exact,NCTId,protocolSection.identificationModule.nctId,False,True,True,False,False,False
GPT-5.1,protocolSection.identificationModule.secondaryIdInfos[0].link,EV,EV,,https://www.clinicaltrials.org.uk,,,,SecondaryIdLink,protocolSection.identificationModule.secondaryIdInfos.link,True,False,True,False,False,False
GPT-5.1,protocolSection.identificationModule.briefTitle,TP,TP,Venous Insufficiency and Neuromuscular Stimulation,VeINS Trial of Neuromuscular Electrical Stimulation in Chronic Venous Disease,True,0.93,success,BriefTitle,protocolSection.identificationModule.briefTitle,False,True,True,False,False,False
GPT-5.1,protocolSection.identificationModule.officialTitle,FN,FN,Venous Insufficiency and Neuromuscular Stimulation,,False,0.0,,OfficialTitle,protocolSection.identificationModule.officialTitle,False,True,False,False,False,False
GPT-5.1,protocolSection.descriptionModule.briefSummary,TP,TP,The investigators will be evaluating the immediate and longer term effect of treatment with a medical device on the symptoms of chronic venous disease.,"This pilot clinical trial evaluated whether a wearable neuromuscular electrical stimulation (NMES) device applied to the common peroneal nerve can improve leg vein blood flow, reduce leg swelling, and enhance quality of life in adults with chronic venous disease, compared with its effects in healthy volunteers. Forty subjects (10 healthy and 30 with different patterns of venous disease: superficial insufficiency, deep insufficiency, or deep obstruction) used bilateral NMES devices for 4–6 hours per day, 5 days a week, over 6 weeks. The main hypothesis was that repeated NMES use would enhance venous haemodynamics, reduce oedema, and improve disease severity and patient-reported quality of life, especially in those with more severe venous disease.",True,0.72,success,BriefSummary,protocolSection.descriptionModule.briefSummary,False,True,True,False,False,False
GPT-5.1,protocolSection.descriptionModule.detailedDescription,TP,TP,"STUDY AIMS

1. To obtain ultrasound blood flow and velocity measurements in the leg to compare the hemodynamic profiles obtained using a neuromuscular stimulation device with those obtained at rest.
2. To ascertain if a 6 week protocol of electrical neurostimulation of the muscle pumps in the leg and foot can reduce clinical symptoms and improve quality of life.

METHODS Controlled interventional trial. Group 1 (10 subjects) will be healthy subjects with no clinical venous disease. Subjects with venous incompetence to be recruited into one of three groups. Group 2 (10 subjects) will have superficial venous incompetence; Group 3 (10 subjects) will have deep venous incompetence; Group 4 (10 subjects) will have deep vein occlusion. These will be clinical diagnoses confirmed with duplex ultrasound.

The device used in this study will be the geko™ T-1 device (Firstkind Ltd, UK). A geko™ device will be fitted to each leg. The device stimulation level is set to the minimum level that can achieve the desired response (outward and upward twitching of the foot when raised from the ground).

ENDPOINTS Primary end-point

* Increase in venous flow Secondary end points
* Improvement in clinical symptoms at 6 weeks, as judged by questionnaire
* Reduction in absolute leg diameter and volume at 6 weeks","This controlled interventional trial (VeINS Trial; NCT02137499) investigated the haemodynamic and clinical effects of neuromuscular electrical stimulation (NMES) in healthy subjects and patients with chronic venous disease (CVD). CVD arises from impaired venous return due to superficial or deep venous insufficiency or obstruction, leading to venous hypertension, leg swelling, symptoms, and complications such as venous ulcers. Existing treatments (surgery, compression hosiery, layered bandaging, intermittent pneumatic compression) primarily aim to reduce venous stasis and improve venous return.

The study used the geko™ T‑1 NMES device (Firstkind Ltd, UK), which delivers intermittent transcutaneous electrical stimulation (27 mA, 1 Hz, adjustable pulse width 70–560 μs) to the common peroneal nerve at the knee. This elicits contractions of the anterior and lateral leg muscles to activate the calf muscle pump while the subject is at rest. There was no pre‑existing treatment protocol for venous disease, so the investigators specified a pragmatic regimen: bilateral application of the device for 4–6 hours per day, 5 days a week, for 6 weeks. Subjects were trained to self‑apply and adjust the device, and completed usage diaries.

Forty adults (>18 years) were recruited: 10 healthy volunteers and 30 patients with venous disease. Venous patients were stratified according to duplex ultrasound findings into superficial venous insufficiency, deep venous insufficiency, or deep venous obstruction, recognizing that some had mixed patterns. Exclusion criteria included peripheral arterial disease, leg fracture or metallic implants, and systemic causes of limb swelling (heart, lung, or renal failure). Baseline assessments included medical history, physical examination, pregnancy testing in women, ankle–brachial pressure index, and detailed venous duplex ultrasound with reflux defined as >0.5 s. Disease severity was classified using CEAP clinical class.

The primary physiological outcomes were femoral vein haemodynamic parameters and microcirculatory flow. Venous peak velocity (PV), time‑averaged mean velocity (TAMV), and volume flow (VF) were measured by duplex ultrasound in the right femoral vein 3–5 cm from the saphenofemoral junction. Laser Doppler fluximetry was recorded from the dorsum of the left hand and foot to assess changes in microvascular flux. Measurements were taken after a 10‑minute rest, with the NMES device off, and then 20 minutes after device activation at a comfortable stimulation setting. Haemodynamic testing was repeated at week 6 following the 6‑week NMES usage period.

Leg volume was estimated bilaterally using circumferential measurements at the ankle and maximal calf, along with the vertical distance between them, and applying a truncated inverted cone model to calculate volume. This allowed evaluation of changes in leg oedema over the 6‑week treatment period.

Clinical and patient‑reported outcomes included the Venous Clinical Severity Score (VCSS), Venous Disability Score (VDS), Aberdeen Varicose Vein Questionnaire (AVVQ), EuroQol‑5D (EQ‑5D), Short Form‑12 (SF‑12), and the Center for Epidemiologic Studies Depression Scale (CES‑D). These were collected at baseline (week 0), after treatment (week 6), and two weeks after stopping NMES (week 8) to assess durability of effect. Patients were also grouped by CEAP class into mild disease (C0–3) and severe disease (C4–6) for analysis of quality‑of‑life changes.

Analyses compared demographic and baseline characteristics across groups with ANOVA, and haemodynamic parameters as changes from baseline between healthy subjects and pooled venous patients, as well as between venous subgroups. Normality was tested with the Kolmogorov–Smirnov test; appropriate parametric or non‑parametric tests were then applied, with significance at p<0.05.

Results showed that NMES acutely increased femoral peak velocity, TAMV, and volume flow in patients with venous disease, with gains generally smaller in deep venous disease and obstruction. Regular use over 6 weeks further enhanced PV and TAMV in both healthy and diseased subjects. Laser Doppler fluximetry increased markedly in the leg and arm, indicating improved microcirculatory flow, although leg responses were attenuated in deep venous disease. Over 6 weeks, unilateral leg volume decreased by approximately 12% in venous patients, indicating a clinically meaningful reduction in oedema, whereas healthy participants showed minimal change.

Quality‑of‑life and clinical severity scores tended to improve among patients with venous pathology, particularly those with severe disease (CEAP C4–6), with reductions in VDS and AVVQ scores and improvements in SF‑12. The only statistically significant change was an improvement in VDS from week 0 to week 6, but several changes were considered clinically relevant. Improvements in venous clinical scores persisted two weeks after stopping NMES.

About 23% of subjects, all with severe venous disease and higher BMI, did not exhibit a visible muscle twitch at maximum device output, limiting treatment effectiveness in these individuals. Devices were generally well tolerated; some participants experienced skin irritation at the application site, which resolved with cessation and topical emollients.

In summary, the study demonstrates that NMES via a portable peroneal nerve stimulator can acutely and chronically improve venous haemodynamics, reduce leg oedema, and potentially improve quality of life in patients with chronic venous disease. The therapy may be useful as an adjunctive measure in chronic venous insufficiency and may have a role in venous thromboembolism prophylaxis where anticoagulation or compression is limited, though thrombosis outcomes were not directly assessed in this trial.",True,0.94,success,DetailedDescription,protocolSection.descriptionModule.detailedDescription,False,True,True,False,False,False
GPT-5.1,protocolSection.conditionsModule.conditions,TP,FP,"['Chronic Venous Disease', 'Venous Insufficiency', 'Deep Venous Obstruction']","['Chronic Venous Insufficiency', 'Varicose Veins', 'Venous Thromboembolism', 'Deep Vein Thrombosis', 'Venous Ulcer', 'Edema', 'Venous Insufficiency, Deep', 'Venous Obstruction']",False,0.0,disjoint,Condition,protocolSection.conditionsModule.conditions,False,True,True,False,False,False
GPT-5.1,protocolSection.conditionsModule.keywords,TP,FP,"['Deep venous obstruction', 'Venous insufficiency']","['Chronic Venous Disease', 'Superficial Venous Insufficiency', 'Deep Venous Insufficiency', 'Deep Venous Obstruction', 'Varicose Veins', 'Venous Hypertension', 'Leg Edema', 'Venous Ulcer', 'Venous Thromboembolism', 'Deep Vein Thrombosis', 'Neuromuscular Electrical Stimulation', 'NMES', 'geko device', 'Venous Hemodynamics', 'Femoral Vein Flow', 'Laser Doppler Fluximetry', 'Calf Muscle Pump', 'Intermittent Pneumatic Compression', 'Quality of Life', 'Venous Clinical Severity Score', 'Venous Disability Score', 'Aberdeen Varicose Vein Questionnaire']",False,0.5,partial,Keyword,protocolSection.conditionsModule.keywords,False,True,True,False,False,False
GPT-5.1,protocolSection.designModule.studyType,TP,TP,INTERVENTIONAL,INTERVENTIONAL,True,1.0,exact,StudyType,protocolSection.designModule.studyType,False,True,True,False,True,False
GPT-5.1,protocolSection.designModule.patientRegistry,EV,EV,,False,,,,PatientRegistry,protocolSection.designModule.patientRegistry,True,False,True,False,False,False
GPT-5.1,protocolSection.designModule.phases,TP,TP,['NA'],['NA'],True,1.0,exact,Phase,protocolSection.designModule.phases,False,True,True,False,True,False
GPT-5.1,protocolSection.designModule.designInfo.allocation,TP,TP,NON_RANDOMIZED,NON_RANDOMIZED,True,1.0,exact,DesignAllocation,protocolSection.designModule.designInfo.allocation,False,True,True,False,True,False
GPT-5.1,protocolSection.designModule.designInfo.interventionModel,TP,TP,PARALLEL,PARALLEL,True,1.0,exact,DesignInterventionModel,protocolSection.designModule.designInfo.interventionModel,False,True,True,False,True,False
GPT-5.1,protocolSection.designModule.designInfo.interventionModelDescription,EV,EV,,"Controlled interventional feasibility trial with four predefined groups (healthy, superficial venous insufficiency, deep venous insufficiency, deep venous obstruction) all receiving the same NMES intervention and compared across groups.",,,,DesignInterventionModelDescription,protocolSection.designModule.designInfo.interventionModelDescription,True,False,True,False,False,False
GPT-5.1,protocolSection.designModule.designInfo.observationalModel,EV,EV,,COHORT,,,,DesignObservationalModel,protocolSection.designModule.designInfo.observationalModel,True,False,True,False,False,False
GPT-5.1,protocolSection.designModule.designInfo.timePerspective,EV,EV,,PROSPECTIVE,,,,DesignTimePerspective,protocolSection.designModule.designInfo.timePerspective,True,False,True,False,False,False
GPT-5.1,protocolSection.designModule.designInfo.maskingInfo.masking,TP,TP,NONE,NONE,True,1.0,exact,DesignMasking,protocolSection.designModule.designInfo.maskingInfo.masking,False,True,True,False,True,False
GPT-5.1,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,EV,EV,,"Open-label study; no mention of blinding of participants, care providers, investigators, or outcomes assessors.",,,,DesignMaskingDescription,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,True,False,True,False,False,False
GPT-5.1,protocolSection.designModule.enrollmentInfo.count,TP,TP,40,40,True,1.0,exact,EnrollmentCount,protocolSection.designModule.enrollmentInfo.count,False,True,True,False,False,False
GPT-5.1,protocolSection.outcomesModule.secondaryOutcomes[3].measure,EV,EV,,Change in disease-specific quality of life (Aberdeen Varicose Vein Questionnaire),,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
GPT-5.1,protocolSection.outcomesModule.secondaryOutcomes[4].measure,EV,EV,,Change in generic quality of life (SF-12),,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
GPT-5.1,protocolSection.outcomesModule.secondaryOutcomes[5].measure,EV,EV,,Change in generic quality of life (EQ-5D),,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
GPT-5.1,protocolSection.outcomesModule.secondaryOutcomes[6].measure,EV,EV,,Change in depressive symptoms (CES-D Scale),,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
GPT-5.1,protocolSection.outcomesModule.secondaryOutcomes[3].description,EV,EV,,"Change in patient-reported disease-specific quality of life as measured by the Aberdeen Varicose Vein Questionnaire (AVVQ), including assessment of changes after cessation of NMES.",,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
GPT-5.1,protocolSection.outcomesModule.secondaryOutcomes[4].description,EV,EV,,"Change in generic health-related quality of life assessed by the Short Form-12 (SF-12) questionnaire, with results interpreted by venous disease severity groups (CEAP C0-3 vs C4-6).",,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
GPT-5.1,protocolSection.outcomesModule.secondaryOutcomes[5].description,EV,EV,,Change in generic health-related quality of life assessed by the EuroQol-5D (EQ-5D) questionnaire in subjects with venous disease.,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
GPT-5.1,protocolSection.outcomesModule.secondaryOutcomes[6].description,EV,EV,,Change in mood and depressive symptoms assessed by the Center for Epidemiologic Studies Depression (CES-D) Scale.,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
GPT-5.1,protocolSection.outcomesModule.secondaryOutcomes[3].timeFrame,EV,EV,,"Weeks 0, 6, and 8",,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
GPT-5.1,protocolSection.outcomesModule.secondaryOutcomes[4].timeFrame,EV,EV,,"Weeks 0, 6, and 8",,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
GPT-5.1,protocolSection.outcomesModule.secondaryOutcomes[5].timeFrame,EV,EV,,"Weeks 0, 6, and 8",,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
GPT-5.1,protocolSection.outcomesModule.secondaryOutcomes[6].timeFrame,EV,EV,,"Weeks 0, 6, and 8",,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
GPT-5.1,protocolSection.outcomesModule.otherOutcomes[0].measure,EV,EV,,Device tolerability and skin irritation,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
GPT-5.1,protocolSection.outcomesModule.otherOutcomes[1].measure,EV,EV,,Self-reported NMES device usage,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
GPT-5.1,protocolSection.outcomesModule.otherOutcomes[2].measure,EV,EV,,Proportion of participants in whom NMES fails to elicit muscle twitch,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
GPT-5.1,protocolSection.outcomesModule.otherOutcomes[0].description,EV,EV,,"Incidence of skin irritation, discontinuation due to irritation, and patient-reported tolerability of NMES use, including whether device use interfered with activities of daily living or mobilisation.",,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
GPT-5.1,protocolSection.outcomesModule.otherOutcomes[1].description,EV,EV,,"Patient-reported duration and frequency of NMES device activation, recorded in a usage diary (hours per day and days per week of use).",,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
GPT-5.1,protocolSection.outcomesModule.otherOutcomes[2].description,EV,EV,,Number and characteristics of subjects in whom the NMES device was ineffective (unable to elicit dorsiflexion/muscle twitch) at maximum stimulation.,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
GPT-5.1,protocolSection.outcomesModule.otherOutcomes[0].timeFrame,EV,EV,,Throughout the 6-week NMES usage period and at week 6 assessment,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
GPT-5.1,protocolSection.outcomesModule.otherOutcomes[1].timeFrame,EV,EV,,Over the 6-week home-use period,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
GPT-5.1,protocolSection.outcomesModule.otherOutcomes[2].timeFrame,EV,EV,,At initial device fitting and early activation period (baseline),,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
GPT-5.1,protocolSection.eligibilityModule.eligibilityCriteria,TP,TP,"Group 1

* Inclusion criteria - 18+ years old, 17\<BMI\<30
* Exclusion criteria - Heart/lung/kidney failure, pregnancy, diagnosis of peripheral vascular disease, previous VTE, ABPI\<0.9, active infection, previous leg fracture or metal implant in leg

Group 2

* Inclusion criteria - 18+ years old, 17\<BMI\<30, clinical diagnosis of superficial venous insufficiency (CEAP C2-6) confirmed with duplex US
* Exclusion criteria - Heart/lung/kidney failure, pregnancy, ABPI\<0.9, active infection, previous leg fracture or metal implant in leg

Group 3

* Inclusion criteria - 18+ years old, 17\<BMI\<30, clinical diagnosis of deep venous insufficiency (CEAP C2-6) confirmed with duplex US
* Exclusion criteria - Heart/lung/kidney failure, pregnancy, ABPI\<0.9, active infection, previous leg fracture or metal implant in leg

Group 4

* Inclusion criteria - 18+ years old, 17\<BMI\<30, clinical diagnosis of deep venous obstruction confirmed with duplex US
* Exclusion criteria - Heart/lung/kidney failure, pregnancy, ABPI\<0.9, active infection, previous leg fracture or metal implant in leg","- Inclusion Criteria:
  - Age over 18 years
  - Ability to provide written informed consent

- Exclusion Criteria:
  - History of peripheral arterial disease
  - History of leg fracture
  - Presence of metallic implant in the leg
  - Systemic causes of limb swelling, including:
    - Heart failure
    - Lung failure
    - Renal failure
  - (Females) Positive pregnancy test",True,0.86,success,EligibilityCriteria,protocolSection.eligibilityModule.eligibilityCriteria,False,True,True,False,False,False
GPT-5.1,protocolSection.eligibilityModule.healthyVolunteers,TP,TP,True,True,True,1.0,exact,HealthyVolunteers,protocolSection.eligibilityModule.healthyVolunteers,False,True,True,False,False,False
GPT-5.1,protocolSection.eligibilityModule.sex,TP,TP,ALL,ALL,True,1.0,exact,Sex,protocolSection.eligibilityModule.sex,False,True,True,False,True,False
GPT-5.1,protocolSection.eligibilityModule.minimumAge,TP,TP,18 Years,18 Years,True,1.0,exact,MinimumAge,protocolSection.eligibilityModule.minimumAge,False,True,True,False,False,False
GPT-5.1,protocolSection.eligibilityModule.maximumAge,EV,EV,,N/A,,,,MaximumAge,protocolSection.eligibilityModule.maximumAge,True,False,True,False,False,False
GPT-5.1,protocolSection.eligibilityModule.stdAges,TP,TP,"['ADULT', 'OLDER_ADULT']","['ADULT', 'OLDER_ADULT']",True,1.0,exact,StdAge,protocolSection.eligibilityModule.stdAges,False,True,True,False,True,False
GPT-5.1,protocolSection.eligibilityModule.studyPopulation,EV,EV,,,,,,StudyPopulation,protocolSection.eligibilityModule.studyPopulation,True,False,True,False,False,False
GPT-5.1,protocolSection.eligibilityModule.samplingMethod,EV,EV,,,,,,SamplingMethod,protocolSection.eligibilityModule.samplingMethod,True,False,True,False,False,False
